Literature DB >> 14715550

Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.

Sandra Romero-Steiner1, Willie Spear, Nekeidra Brown, Patricia Holder, Thomas Hennessy, Patricia Gomez De Leon, George M Carlone.   

Abstract

We evaluated alamarBlue as a metabolic indicator in a standardized assay for the measurement of serum bactericidal activity (SBA) to Haemophilus influenzae type b (Hib) using sera containing natural and vaccine-induced anticapsular (polyribosylribitol phosphate) antibodies. SBA assays with a colorimetric and a fluorometric end point in the presence of alamarBlue were developed and compared to a standard SBA assay, where colony counts are performed to determine the titer (12). A colorimetric end point required a spectrophotometer, whereas a fluorometric end point required a fluorometer. Prevaccination sera (n = 27) and postvaccination sera (n = 13) were tested by all three methodologies, and the SBA titers obtained in the presence of alamarBlue were compared to those from the standard method. Both the colorimetric and the fluorometric SBA titers were significantly correlated (r = 0.87 and r = 0.95, respectively) with those of the standard assay (>/= 50% killing as the SBA titer end point), and titers were not significantly different when compared to those of the standard assay (P > 0.68). However, the fluorometric end point had superior performance and ease of titer determination compared to the colorimetric end point (95 versus 87% of SBA titers were within 2 dilutions of the standard titer). Hib SBA assays with alamarBlue are reproducible, faster (same-day assay), and easier to perform than the standardized assay, which requires manual or automated colony counts. These semiautomated methodologies result in increased sample throughput and collection of data in digital formats that can be exported to data analysis programs for determination of SBA titers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715550      PMCID: PMC321360          DOI: 10.1128/cdli.11.1.89-93.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  13 in total

1.  Haemophilus influenzae type B infection.

Authors:  O Levine; J Wenger; Y B Perkins; N Rosenstein; A Schuchat
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

2.  Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.

Authors:  K T Mountzouros; A P Howell
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

3.  Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska.

Authors:  K Galil; R Singleton; O S Levine; M A Fitzgerald; L Bulkow; M Getty; B A Perkins; A Parkinson
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

4.  Development of an antimicrobial susceptibility testing method suitable for performance during space flight.

Authors:  J H Jorgensen; J A Skweres; S K Mishra; M L McElmeel; L A Maher; R Mulder; M V Lancaster; D L Pierson
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

5.  Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1987-1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-10-25       Impact factor: 17.586

6.  Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate).

Authors:  S Romero-Steiner; J Fernandez; C Biltoft; M E Wohl; J Sanchez; J Feris; S Balter; O S Levine; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

7.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  H Käyhty; H Peltola; V Karanko; P H Mäkelä
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

8.  Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.

Authors:  Y Schlesinger; D M Granoff
Journal:  JAMA       Date:  1992-03-18       Impact factor: 56.272

9.  Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5.

Authors:  R Schneerson; J B Robbins
Journal:  N Engl J Med       Date:  1975-05-22       Impact factor: 91.245

10.  Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis.

Authors:  D M Yajko; J J Madej; M V Lancaster; C A Sanders; V L Cawthon; B Gee; A Babst; W K Hadley
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

View more
  12 in total

1.  Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a.

Authors:  Nadine G Rouphael; Sarah Satola; Monica M Farley; Karen Rudolph; Daniel S Schmidt; Patricia Gomez-de-León; John B Robbins; Rachel Schneerson; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

2.  Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae.

Authors:  Kathryn T Bieging; Gowrisankar Rajam; Patricia Holder; Ross Udoff; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

3.  The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.

Authors:  Ishac Nazi; John G Kelton; Mark Larché; Denis P Snider; Nancy M Heddle; Mark A Crowther; Richard J Cook; Alan T Tinmouth; Joy Mangel; Donald M Arnold
Journal:  Blood       Date:  2013-07-12       Impact factor: 22.113

4.  Recognition of conserved antigens by Th17 cells provides broad protection against pulmonary Haemophilus influenzae infection.

Authors:  Wenchao Li; Xinyun Zhang; Ying Yang; Qingqin Yin; Yan Wang; Yong Li; Chuan Wang; Sandy M Wong; Ying Wang; Howard Goldfine; Brian J Akerley; Hao Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

Review 5.  A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.

Authors:  Alexander C Maue; Frédéric Poly; Patricia Guerry
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

6.  Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era.

Authors:  Eli B Nix; Nicole Hawdon; Sean Gravelle; Birubi Biman; Malcolm Brigden; Saleem Malik; William McCready; Garry Ferroni; Marina Ulanova
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

7.  Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies.

Authors:  Sandra Romero-Steiner; Patricia F Holder; Patricia Gomez de Leon; Willie Spear; Thomas W Hennessy; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

8.  Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis.

Authors:  Puiying A Mak; George F Santos; Kelly-Anne Masterman; Jeff Janes; Bill Wacknov; Kay Vienken; Marzia Giuliani; Ann E Herman; Michael Cooke; M Lamine Mbow; John Donnelly
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

9.  A Novel Luminescence-Based Serum Bactericidal Assay for Vibrio cholerae Reduces Assay Variation, Is Time- and Cost-Effective, and Directly Measures Continuous Titer Values.

Authors:  Taylor A Wahlig; Ben J Brintz; Melanie Prettyman; Andrew S Azman; Daniel T Leung
Journal:  Am J Trop Med Hyg       Date:  2021-07-08       Impact factor: 2.345

10.  Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants.

Authors:  Kyung Hyo Kim; Hyunju Lee; Eun Hee Chung; Jin Han Kang; Jong Hyun Kim; Jung Soo Kim; Hoan Jong Lee; Sung Hee Oh; Eun Ae Park; Su-Eun Park
Journal:  J Korean Med Sci       Date:  2008-12-23       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.